Christopher A Horvath

US Patent:

6352832, Mar 5, 2002

Filed:

Jul 22, 1999

Appl. No.:

09/359193

Inventors:

Gregory J. LaRosa - West Roxbury MA
Christopher Horvath - Taunton MA
Walter Newman - Boston MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

G01N 3353

US Classification:

435 71, 435 5, 435345, 435343, 4353432, 436548

Abstract:

The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

6696550, Feb 24, 2004

Filed:

Apr 23, 2001

Appl. No.:

09/840459

Inventors:

Gregory J. LaRosa - Newton MA
Christopher Horvath - Taunton MA
Walter Newman - Boston MA
S. Tarran Jones - Radlett, GB
Siobhan H. OBrien - London, GB
Theresa OKeefe - Waltham MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 1600

US Classification:

53038823, 5303871, 5303873, 4241301, 4241331, 4241561

Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

6727349, Apr 27, 2004

Filed:

Feb 3, 2000

Appl. No.:

09/497625

Inventors:

Gregory J. LaRosa - Newton MA
Christopher Horvath - Taunton MA
Walter Newman - Boston MA
S. Tarran Jones - Radlett, GB
Siobhan H. OBrien - Finchley, GB
Theresa OKeefe - Waltham MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 1600

US Classification:

5303873, 4241301, 4241561, 5303871, 53038823

Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

7442775, Oct 28, 2008

Filed:

Jan 27, 2004

Appl. No.:

10/766610

Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Radlett, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 23/00
A61K 39/00
C12N 15/00

US Classification:

5303879, 536 2353, 4353201, 435328

Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

7473421, Jan 6, 2009

Filed:

Jan 27, 2004

Appl. No.:

10/766773

Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Radlett, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 16/00
A61K 39/02

US Classification:

4241391, 435 696, 435 5

Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

7566450, Jul 28, 2009

Filed:

Oct 26, 2007

Appl. No.:

11/924794

Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher J. Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Hertfordshire, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395

US Classification:

4241391, 4241421, 4241431

Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

8227211, Jul 24, 2012

Filed:

Sep 23, 2008

Appl. No.:

12/235765

Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Hertfordshire, GB
Siobhan H. O'Brien - Herts, GB
Theresa O'Keefe - Waltham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395
C12N 15/13
C07K 16/00

US Classification:

435 696, 43525231, 43525233, 43525411, 435375, 4241331, 5303873

Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

US Patent:

20060062793, Mar 23, 2006

Filed:

Sep 2, 2005

Appl. No.:

11/218813

Inventors:

Iain Webb - Boston MA, US
Christopher Horvath - Taunton MA, US

International Classification:

A61K 39/395

US Classification:

424155100

Abstract:

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.